HIV and Aging
Peter W. Hunt, MD
Associate Professor of Medicine, HIV/AIDS Division
University of California, San Francisco, CA
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2015. All rights reserved.
Peter Hunt is an Associate Professor of Medicine in the HIV/AIDS division at the University of California San Francisco and Vice Chair of the AIDS Clinical Trials Group’s Inflammation and End Organ Disease Transformative Science Group. His primary research focus is on the inflammatory consequences of HIV infection. His clinic-based translational research program seeks to understand both the causes and consequences of persistent immune activation both in the presence and the absence of antiretroviral therapy. He collaborates extensively with a multi-disciplinary team of investigators to assess the impact of persistent immune activation on mortality and chronic diseases associated with aging (i.e., cardiovascular disease) as well as on the persistence of HIV in cellular reservoirs. He also conducts pilot clinical trials of novel immune-based interventions designed to decrease immune activation. Dr. Hunt also leads a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting and has helped develop a large mucosal immunology program at San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection.
At the completion of this educational session, learners will:
- Know that HIV increases the risk of several, but not all, age-associated morbidities.
- Be aware that immune activation persists despite suppressive ART and predicts many of these morbidities.
- Understand that some immunologic mechanisms that drive morbidity/mortality in treated-HIV-infection may be distinct from those in aging.
- Appreciate the interventional targets that are being pursued in interventional trials to reduce morbidity and mortality during ART-mediated viral suppression.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and ViiV Healthcare.
To obtain CME credit for this and other PRN programs, please visit the
PRN Courses page at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.
